GLP-1 & compounded medication availability in South Dakota (2026)
South Dakota’s regulators communicate more than most quiet states: the board’s newsletters relay federal compounding developments to its licensees on the record, including a dated January 2024 advisory about counterfeit semaglutide. That makes this page unusual among baseline states, since there is a real state document to cite, without making the state restrictive: eight of our ten lines ship to South Dakota, and the advisory concerns product integrity, not shipping.
South Dakota, line by line
| Product line | Available in South Dakota? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Subject of the board’s January 2024 counterfeit advisory, cited below; ships normally. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same national flat price as every state. |
| NAD+ | Yes | 8–10 business days | Standard telehealth ordering, no state wrinkles. |
| Sermorelin | Yes | 8–10 business days | Dispensed by nonresident-licensed partner pharmacies. |
| Glutathione | No | N/A | A gap in our catalog today, listed as one. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; the cited record is below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; citations in its section below. |
| KPV | No | N/A | Not in the OrderlyMeds formulary anywhere, since it is not an injectable line. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; see its cited section. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its own distinct federal record is below. |
Reviewed November 16, 2026. The two No rows are OrderlyMeds catalog facts, not South Dakota rules. The state document cited below is an integrity advisory, not a gate.
The research-peptide picture for South Dakota
Nothing in South Dakota’s rulebook singles these five out, so the answer here is the national one: BPC-157, TB-500, Epitalon and MOTS-c are dispensed by OrderlyMeds as compounded injectables on patient-specific prescriptions; KPV is not dispensed at all, being no injectable. Read each section’s cited federal record before ordering any of them. FDA’s safety position and the current compounding pathway are stated per substance, identically whether that substance ships to you or not.
BPC-157 in South Dakota
South Dakota orders for BPC-157 are dispensed as a compounded injectable, on a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in South Dakota
TB-500 ships to South Dakota as a compounded injectable, on a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in South Dakota
KPV is outside the OrderlyMeds catalog in every state, because our peptide lines are compounded as injectables and KPV is not.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in South Dakota
Epitalon is dispensed to South Dakota addresses as a compounded injectable.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in South Dakota
MOTS-c ships to South Dakota as a compounded injectable; its federal record, below, is not the four older lines’ wording.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What South Dakota’s pharmacy regulators say about compounded medications
South Dakota’s board is a communicator. Rather than inventing state-specific categories, it relays the federal compounding picture to its licensees through dated newsletters, which is why this page can cite something most baseline states cannot: an on-the-record state advisory touching compounded semaglutide directly. Read what it is and is not: a warning about counterfeits and improper salt forms in the supply chain, not a position against compounded GLP-1s reaching South Dakota patients.
South Dakota licenses pharmacies and regulates compounding under SDCL ch. 36-11 and board rules; it has published no rule singling out GLP-1 medications or peptide lines. Source: South Dakota Board of Pharmacy.
An out-of-state pharmacy shipping prescription drugs to South Dakota patients must hold a nonresident pharmacy license from the South Dakota Board of Pharmacy, renewed annually with a June 30 expiration. Source: SD Board of Pharmacy — Nonresident pharmacy application.
The board’s January 2024 newsletter relayed FDA warnings about counterfeit semaglutide in the supply chain and the restriction of compounding to the semaglutide base form — a product-integrity advisory to licensees, not a shipping restriction. Source: SD Board of Pharmacy — January 2024 newsletter.
South Dakota permits the provider-patient relationship to be established through a face-to-face examination using real-time audio and visual technology (SDCL 34-52-3, 34-52-5); its ban on prescribing from a questionnaire alone applies to controlled substances, which none of the medications on this page are (SDCL 34-52-6). Source: SDCL ch. 34-52 — Telehealth.
An order to Sioux Falls or Rapid City therefore runs the ordinary route: online eligibility, a real-time video evaluation with a provider authorized for South Dakota, a patient-specific prescription filled by a nonresident-licensed partner pharmacy, and tracked delivery inside the published 8–10 business-day window. Pricing is the national flat price, and the advisory above changes nothing about cost or access.
South Dakota availability FAQs
Does compounded semaglutide ship to South Dakota?
Yes. Compounded semaglutide and compounded tirzepatide both ship to South Dakota addresses, from $74/month for new semaglutide customers in their first two months.
What was South Dakota’s January 2024 semaglutide advisory?
A board newsletter item relaying FDA warnings about counterfeit semaglutide and improper salt forms in the supply chain. It is cited in the regulator section above. It concerns product integrity, and ordering through a licensed pharmacy on a patient-specific prescription is exactly the path it points to.
Can I order BPC-157 or MOTS-c to a South Dakota address?
Yes, both ship as compounded injectables on patient-specific prescriptions, as do TB-500 and Epitalon. KPV does not ship in any state. Each substance’s own cited federal record sits in its section above.
How long do South Dakota deliveries take?
The published window is 8–10 business days from signup, tracked throughout.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
